Early Albumin Administration in Veno‐Arterial Extracorporeal Membrane Oxygenation
Artificial Organs · 2025
DOI: 10.1111/aor.14934 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Artificial Organs, 2025. Verfasst von Tobias Wengenmayer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Medical Intensive Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau,…. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Albumins, Fluid Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The clinical outcome and fluid balance of patients with veno‐arterial extracorporeal membrane oxygenation (VA ECMO) or after extracorporeal cardiopulmonary resuscitation (eCPR) may be improved by addressing the high fluid demand with an early albumin administration.
Methods
In this prospective observational study, patients supported with VA ECMO or eCPR received early albumin administration (25 g/L) to prime the VA ECMO system. These patients were compared to patients who received a regimen based solely on balanced crystalloids (crystalloid group) or a regimen based on a 1:4 volume mixture of albumin (10 g/L) and balanced crystalloids (albumin group).
Results
660 VA ECMO patients (66.4% eCPR) treated between January 2017 and June 2021 were analyzed, whereby 265 patients received crystalloid fluid therapy, 269 patients received albumin therapy, and 126 patients received early albumin therapy. When compared to the albumin and crystalloid groups, patients in the early albumin treatment group had significantly lower cumulative fluid balances ( p < 0.05). However, this effect was only observed in the group of eCPR patients and not in patients with cardiogenic shock. Logistic regression revealed albumin administration as an independent predictor of increased survival (Odds ratio 1.66 (1.11–2.47) [95%‐CI], p = 0.013). Yet, only eCPR patients showed a survival benefit from albumin administration compared to the crystalloid group (survival of 29.4% vs. 18.8%, p = 0.024).
Conclusion
Early albumin administration in eCPR patients was linked to a significant decline in fluid balance. Moreover, volume therapy with albumin application was an independent predictor for improved survival in eCPR patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Medical Intensive Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
- Department of Cardiology and Angiology, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
- Institute of Medical Biometry and Statistics, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
- Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.
ORCID-Profile: Markus Jäckel, Alexander Supady
Zitieren
APA
Wengenmayer, T., Hirth, M. L., Jäckel, M., Bemtgen, X., Kaier, K., Biever, P. M., Supady, A., Maulhardt, T., Westermann, D., Staudacher, D. L., & Rilinger, J. (2025). Early Albumin Administration in Veno‐Arterial Extracorporeal Membrane Oxygenation. Artificial Organs. https://doi.org/10.1111/aor.14934
Vancouver
Wengenmayer T, Hirth ML, Jäckel M, Bemtgen X, Kaier K, Biever PM, et al. Early Albumin Administration in Veno‐Arterial Extracorporeal Membrane Oxygenation. Artificial Organs. 2025. doi:10.1111/aor.14934
BibTeX
@article{Wengenmayer2025,
author = {Wengenmayer, Tobias and Hirth, Marvin L and Jäckel, Markus and Bemtgen, Xavier and Kaier, Klaus and Biever, Paul M and Supady, Alexander and Maulhardt, Thomas and Westermann, Dirk and Staudacher, Dawid L and Rilinger, Jonathan},
title = {Early Albumin Administration in Veno‐Arterial Extracorporeal Membrane Oxygenation},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.14934}
}
EUVIMED